



UNIVERSITY OF HAWAII
CANCER CENTER

CBP/TCR
FACULTY RECRUITMENT SEMINAR

“NCI's Precision Medicine Initiative”



Alice P. Chen, M.D.

Head, Early Clinical Trials Development Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute

Monday, August 13, 2018
12:00 Noon, Sullivan Conference Center
UH Cancer Center
Light refreshments to follow

ALICE P. CHEN, M.D.

CURRICULUM VITAE

EDUCATION:

1979-1982 University of Tennessee, Early admission to medical school
1982-1986 M.D., University of Tennessee

CURRENT POSITIONS AND APPOINTMENTS AT NCI

12/2014 - present: Head, Early Clinical Trials Development Program

As the Head of the Early Clinical Trials Development Program (ECTDP), I lead the Developmental Therapeutics Clinic. Within this ECTDP program, NCI facilitates the discovery and development of new anticancer drugs and drug targets, as well as piloting novel clinical trial designs that can be applied to the development of molecularly targeted agents on a national and international basis. The Developmental Therapeutics Clinic (DTC) is part of the ECTDP. I oversee ~ 20 active early phase clinical trials as well as the coordinating center for several phase I and phase II trials. I oversee all DTC activities including the supervision of the clinical staff, and manage the DTC budget. I provide expert clinical advice and leadership in the development of strategies for addressing a wide range of issues regarding the entire Phase I Clinical Trials process. I am a senior clinical advisor on NCI Phase I Clinical Trials, and am a liaison between the intramural and extramural communities on all aspects of these trials, including design and conduct, including such critical issues as the accuracy of the measurements of the agent's effect on the target of interest in the patient, and the ability to gauge what the starting dose might be to ensure aggressive dose escalation or limiting the required number of dose levels. I have authored manuscripts describing research activities of the DTC and made presentations before scientific groups on significant achievements in the research undertaken, representing DCTD at local, national, and international meetings.

RECENT POSITIONS

01/2005 - 11/2014 (detailed to ECTDP): Medical Officer at the Investigational Drug Branch, Cancer Therapy Evaluation Program, NCI

As a Medical Officer, I formulated drug development plans for agents in my portfolio. During my time at CTEP, I brought into CTEP several agents for development, especially in the DNA Repair pathway. I work with basic scientists; preclinical drug development staff of NCI or drug companies; intra- and extramural clinical investigators and staff of the FDA to design development plans that includes translation from laboratory to the bedside. My projects have been presented at ASCO, AACR and EORTC as well as reported in Journal of Clinical Oncology. I served as Program Manager for a portfolio of investigational agents, including PARP inhibitors (veliparib and talazoparib-2 million), HSP 90 inhibitors (AT 13387 and PUH71), and DNA repair inhibitors (AZD 1775 and TRC 102) with combined budget over \$10 million. I consult with oncologists around the world regarding cancer therapeutics decision-making. I led the revision of Common Terminology Criteria Adverse Events (CTCAE) v4 and am the lead for the maintenance and

Chen, Alice P.

2

revision of this document. With interest in patient reported outcomes, I also am in the Strategic Leadership Group for NCI PROCTCAE, Patient-Reported Outcomes Version of the CTCAE. I also assisted NCI Center for Global Health in developing a Memorandum of Understanding with National Taiwan University to collaborate in clinical research. With the recent support of precision medicine at the presidential and institutional level, I am principal investigator to two of NCI sponsored Precision Medicine trials, Molecular Profiling-Based Assignment of Cancer Therapy (NCI MPACT) and Molecular Analysis for Therapy Choice (NCI MATCH). I have authored many articles involving my agents as an investigator or an expert. For my work in various committees, I have won 9 NIH Merit Awards.

01/2010 – 12/2014: Attending Clinician in the Development Therapeutics Clinic (DTC)

I have attended this clinic which specializes in early phase clinical trials including the first phase 0 under the recent FDA guidance on Exploratory IND. I serve as a medical monitor for trials involving my CTEP agents or as an associate investigator for the trials active in the DTC. I also mentor fellows in the Advanced Developmental Therapeutics Training Program. In December 2014, I transitioned to the leadership of the Developmental Therapeutics Clinic.

08/1999 - 08/2004 Medical Oncologist, Cancer Specialists of South Texas, PA

I joined and became a partner of the Cancer Specialists of South Texas within one year. I was the director of our research department which ran phase II-V trials. I started and ran two clinics in underserved areas, Aransas Pass and Rockport, TX. I served on the advisory committee for the Spohn Breast Cancer Program, actively participated in “I Can Cope” class through the American Cancer Society (ACS), chairperson of the ACS Breast Cancer Committee and a member of the First Friday Committee which funds mammograms for indigent patients. I also volunteer at the Spohn Memorial Hospital’s Specialty Clinic providing care to indigent patients. I was a board member of the Christus Spohn Network and the American Cancer Society. I worked in Spohn’s Performance Improvement Committee and Nueces County Medical Society Census and Executive Committee. I was the chair of the Institutional Review Board for Christus Spohn Network and led the IRB through a FDA audit. I also served as an assistant director for AIM Hospice providing care to terminal oncology patients in the Corpus Christi area. I was the only physician in Corpus Christi to be selected as Super Doctor by Texas Monthly magazine in 2004 and 2005.

WORK ADDRESS:

31 Center Drive
Suite 31
3A44
Bethesda, MD 20892
(301)496-4291

CITIZENSHIP:

Naturalized U.S. Citizen, 1975

Chen, Alice P.

3

UNDERGRADUATE EDUCATION:

University of Tennessee
Knoxville, Tennessee
College Scholar
No Degree (early admission to medical school), 1979-1982

MEDICAL EDUCATION:

University of Tennessee
Memphis, Tennessee
M.D., 1982 - 1986

INTERNSHIP:

University of Texas Health Science Center
San Antonio, Texas
1986-1987

RESIDENCY:

Saint Paul Medical Center
Dallas, Texas
Internal Medicine
1987-1989

FELLOWSHIP:

Baylor College of Medicine
Houston, Texas
Medical Oncology
1989-1991

Oncology & Regulatory Sciences Fellowship
Medical Officer Clinical Pharmacologist
CDER, FDA and CTEP, NCI
Bethesda and Rockville, Maryland
1991-1993

EMPLOYMENT RECORDS:

Head, Early Clinical Trials Development Program
OD/DCTD
31 Center Drive, Suite 31, 3A44
Bethesda, MD 20892
12/14 –

Chen, Alice P.

4

Medical Officer
IDB, CTEP, DCTD, NCI
6130 Executive Blvd
Suite 7118
Rockville, MD 20852
01/05-11/14 (detailed to ECTDP)

Medical Oncologist (Clinical)
Cancer Specialists of South Texas, PA
1625 Rodd Field Road
Corpus Christi, Texas 78412
08/1999-08/2004

Medical Oncologist (Clinical)
Cancer Care Associates
1521 S. Staples, Suite 802
Corpus Christi, Texas 78404
07/1998-08/1999

Attending (Clinical)
Research Officer Group, 0-4
Navy Medical Oncology Branch
National Cancer Institute
10/1996-6/1998

Assistant Professor (Clinical)
(GS-15 equivalent)
Uniformed Services University of Health Sciences
Navy Medical Oncology Branch
Bethesda Naval Hospital
Bethesda, MD
07/1993-09/1996

CERTIFICATION:

National Board of Medical Examiners, 1987
FLEX, 1988
Board Certified in Internal Medicine 1999-
Board Certified in Medical Oncology 2013 - 2023
ACRP-Certified Clinical Trial Investigator 2003-2005

MEDICAL LICENSURE:

Texas Medical License, 1988
Florida Medical License, 1997

Chen, Alice P.

5

HOSPITAL APPOINTMENTS:

NCI Clinical Center, Bethesda, MD

ACADEMIC APPOINTMENTS:

Head, Developmental Therapeutics Clinic
ECTDP/DCTD/NCI
2014-

Staff Attending
Developmental Therapeutic Clinic
National Cancer Institute
2005-2014

Medical Officer
IDB/CTEP/DCTD/NCI
Rockville, MD
2005-2014

Assistant Professor
Uniformed Services University of Health Sciences
Bethesda, MD
1993-1996

AWARDS & ACHIEVEMENTS:

University of Tennessee College of Scholars, 1979-1982
Phi Beta Sigma Honor Society, 1980
Alpha Epsilon Delta Honor Society, 1980
Gamma Beta Phi Honor Society, 1980
Recipient of the Alumni Scholarship, University of Tennessee
Recipient of the Estes Kefauver Scholarship, University of Tennessee
Recipient of the Franklin Bonham Scholarship, University of Tennessee
Fellow of the American College of Physicians, 1999
Super Doctor by Texas magazine, 2004, 2005
America's Top Physician 2006
NIH Award of Merit, NCI Team for PRO-CTCAE, 2009
NIH Award of Merit, NCI Adverse Event Group, 2009
NIH Award of Merit, Common Terminology Criteria for Adverse Events (CTCAE) Version 4 Working Group, 2009
NIH Award of Merit, International Clinical Trials Work Group, 2009
On the Spot Award, ACTNOW trials, 2009
NIH Award of Merit, Drug Risk Terminology Team, 2013
NIH NCI Award of Merit, MATCH Development Group, 2015

Chen, Alice P.

6

NIH NCI Award of Merit, CTCAE Core Committee, 2016

NIH NCI Award of Merit, Pro-CTCAE Group, 2016

NIH NCI Award of Merit, Rare Tumor Initiative Team 2017

PROFESSIONAL ACTIVITIES:

ACLS Provider Course

Instructor

Saint Paul Medical Center

April 4-11, 1988; October 3, 1988; May 8, 1989

Introduction to Clinical Medicine II

Instructor

Uniformed Services University of the Health Sciences

January-April 1994, February-April 1996, April-May 1997

Committee for Protection of Human Subjects

Member

National Naval Medical Center Bethesda

April 1994, October 1995

Pharmacology Course (Cancer Chemotherapy)

Instructor

Uniformed Services University of the Health Sciences

1995

PDQ External Advisory Board

Member

NCI

July 1995-1998

Ethical Legal and Social Aspects of Medical Care

Faculty Facilitator

Uniformed Services University of the Health Sciences

August-October 1995, August-October 1997

Third Year Clerkship in Medicine

Preceptor

Uniformed Services University of the Health Sciences

January-February 1996

Working Group in Breast and Gynecologic Cancer

Member

NIH

December 1996-1998

Chen, Alice P.

7

Institutional Review Board
Member
National Naval Medical Center Bethesda
October 1997-1998

Prostate Cancer Guideline Committee
Member
National Naval Medical Center Bethesda
February 1997-1998

Branch Assistant Curriculum Coordinator
Medical Oncology Fellowship-Medicine
NCI
1998

Branch Oncology Curriculum Coordinator
Medical Oncology Fellowship-Medicine
NCI
1998

Memorial Specialty Clinic
Medical Oncologist
July 1998-2004
Corpus Christi, TX

First Friday Committee
Member
1998-2004
Corpus Christi, TX

Spohn Breast Care Program
Member, Advisory Committee
1998-2004
Corpus Christi, TX

Clinical Research Department
Director
Cancer Specialists of South Texas, PA
January 2000-2004

American Cancer Society
Presenter, "I Can Cope" classes
1998-2000
Corpus Christi, TX

Chen, Alice P.

8

Cancer Network

Member

Christus Spohn Network

July 1998-2002

Advisory Board

Member

American Cancer Society

1999-2002

Corpus Christi, TX

American Cancer Society

Board Member

2002-2004

Corpus Christi, TX

Performance Improvement Committee

Member

Corpus Christi Medical Center

January 1999-December 1999

Public Relations Committee

Member

Nueces County Medical Society

1999-2000

Pharmacy and Therapeutics Committee

Member

Christus Spohn Network

January 1999-2000

Institutional Review Board

Chairperson

Christus Spohn Network

January 1999-2004

Census Board

Member

Nueces County Medical Society

1999-2002

Chairperson

2001-2002

Chen, Alice P.

9

Executive Committee

Member

Nueces County Medical Society

1999-2002

Aim Hospice

Assistant Director

2001-2004

Rockport, TX

Performance & Improvement Committee

Member

Christus Spohn Network

2001-2002

Corpus Christi, TX

Breast Cancer Committee

Chairperson

American Cancer Society

2002-2003

Corpus Christi, TX

U01 Program Director for JHU and MSKCC

NCI

2005

CTCAE v 4 Revision

CTEP Lead

Bethesda, MD

2008-2009

CTEP AE Committee

Member

2008-2014

NCI Scientific Oversight Committee for the Development of the Patient-Reported Outcomes
version of the Common Terminology Criteria for Adverse Events

Member

2008-2009

Bethesda, MD

NCI/PRO-CTCAE

Strategic Leadership Group

2008-

Chen, Alice P.

10

International Clinical Trials Working Group

Member

2009-

NCI Core Governance Group for CTCAE

Chair

2009-

CTEP CRF Committee

Lead

2009-2014

Investigational Drug Steering Committee

DNA Repair Task Force

Member

2009-2013

Brain Mets for Breast Cancer Group

Member

2010-

DCTD Pharmacodynamics Group

Member

2010 -

Developmental Therapeutic Clinic Safety Monitoring Committee

Organizer and Executive secretary

2011-2014

NCI Breast Cancer Steering Committee

Member

2011-2014

Concise Informed Consent Working Group on Risks

CTEP

2011-2014

Visit to Taiwan (DOH, FDA, NTUH, AS)

Center Global Health (CGH)

July 2012

East Asia Regional Interest Group

CGH

2012 – 2015

Chen, Alice P.

11

Pediatric Adverse Event Working Group
2013- 2016

Trans-NCI PRO Working Group
Member
2013-

Center for Global Health
Visit to Taiwan
MOU with Taiwan
November 2013

AT 13387 Drug Development Team
Co-lead
2014

VX-984c Drug Development Team
Member
2014

NCI MATCH Steering Committee
Member
2015 -

Center for Global Health
Visit to Taiwan
MOU with Taiwan
January 2015

Pediatric MATCH Steering Committee
Member
2015-

ASCO Educational Book expert panel
Member
2015, 2016, 2017

NCI Colorectal Working Group
Member
2016-

RECIST Committee
Member
2015-

Chen, Alice P.

12

CSRC Post Database Think Tank

Member

2016

Rare Tumor Initiative Steering Committee

Member

2016 –

Attribution Discussion & Conference Planning

Stakeholder

2017

2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Scientific Committee Member

2017

Scholarship Oversight Committee for Julia Cohen

Member

2018 -

COMMUNITY SERVICE:

Birthday Book Club

Windsor Park Elementary School

Co-Chairperson

2004

Coastal Bend Chinese Association

Vice-President

2004

Coastal Education Research and Consortium

Founder and President

2004-2010

Math Olympiad

Wayside Elementary School

2005-2006

Fundraising Vice President

Rockville Chinese School

2006-8

Membership Vice President

Hoover Middle School PTA

2008-9

Chen, Alice P.

13

Communication Director
JY Martial Arts Center
2008-11

Lion Dance Coordinator
Potomac Elementary School
2011,2012

Stroke and Turn Judge
Potomac Valley Swim
2006-
A Team Representative
Potomac Swim and Dive Team
2013-2014

Membership Chair
Boy Scout Troop 773
2013-2016

MILITARY SERVICE:

Public Health Service
Lieutenant Commander
July 1991-July 1993
Senior Assistant Surgeon (O-3)
October 1996-June 1998
Surgeon(O-4)

PRIMARY INVESTIGATOR:

NCI Molecular Analysis for Therapy Choice (NCI MATCH)

Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors (MPACT)

Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in Patients with Refractory Solid Tumor

Phase I Trial of the Combination of the Heat Shock Protein-90 (HSP9) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT 7519 in Patients with Advanced Solid tumor (site PI)

Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults with Refractory Solid Tumors

Chen, Alice P.

14

A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas

A Phase I Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas

A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma

A Phase II Trial in Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations (Closed to Accrual)

Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas (Completed)

A Phase I Trial of Weekly Indenoisoquinoline LMP400 in Adults With Relapsed Solid Tumors and Lymphomas (Completed)

Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults with Refractory Solid Tumors (Completed)

Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors (Completed)

PUBLICATIONS:

AP Chen, JL Grem: "Antimetabolites" *Current Opinions in Oncology* 4 (6): 1089-1098, 1992.

Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Steinberg SM, Arbuck SG, Beveridge RA, Kales AN, Miller JA, Weiss RB, McAtee N, Chen A, Goldspiel B, Sover E, Allegra CJ: "Phase II Study of Fluorouracil, Leucovorin, and Interferon Alfa-2a in Metastatic Colorectal Carcinoma *JCO* II (9): 1737-1745, 1993.

Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Csyk R, Arbuck SG, Sorensen JM, Chen AP, Goldstein L, Jordan E, Setser A, Goldspiel B, DeCarvalho M, Allegra CJ: "A Phase I Study of Continuous Infusion 5-Fluorouracil plus Calcium Leucovorin in Combination with N-(Phosphonacetyl) L-aspartate in Metastatic Gastrointestinal Adenocarcinoma". *Cancer Research* 53: 4828-4836, 1993.

Chen, Alice P.

15

Grem JL, McAtee N, Murphy RF, Hamilton JM, Balis F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A, Kohler DR, Kotite B, Allegra CJ: "Phase I and Pharmacokinetic Study of Recombinant Humana Granulocyte-Macrophage Colony Stimulation Factor Given in Combination with Fluorouracil plus Calcium Leucovorin in metastatic Gastrointestinal Adenocarcinoma" *JCO* 12 (3): 560-568, 1994.

M Politi, F Xie, W Dahut, H Ford, JA Kelly, A Bastian, A Setser, CJ Allegra, AP Chen, JM Hamilton, SF Arbuck, P Linz, H Brammer, and JL Grem: "Phase I Clinical Trial of Continuous Infusion Cyclophosphamide" *Cancer Chemotherapy and Pharmacology* 36 (6): 513-523, 1995.

W Dahut, N Harold, C Takimoto, C Allegra, AP Chen, JM Hamilton, S Arbuck, M Sorenson, F Grollman, H Nakashima, R Lieberman, M Liang, W Corse, and JL Grem: "A Phase I and Pharmacologic Study of 9-Aminocamptothecin Given by 72-Hour Infusion in Adult Cancer Patients" *JCO* 14 (4): 1236-1244, 1996.

Takimoto C, Dahut W, Harold N, Nakashima H, Lieberman R, Liang MD, Arbuck SG, Chen AP, Hamilton JM, Cantilena LF, Allegra CJ, Grem JL: "Clinical pharmacology of 9-aminocamptothecin." *Ann N Y Acad Sci* 1996 Dec 13;803:324-6.

CH Takimoto, W Dahut, H Nakashima, MD Liang, N Harold, R Lieberman, SG Arbuck, AP Chen, JM Hamilton, LR Cantilena, CJ Allegra and JL Grem: "Pharmacokinetic and Pharmacodynamics of a 72-Hour Infusion of 9-Aminocamptothecin in Adult Cancer Patients" *JCO* 15 (4): 1492-1501, 1997.

Grem JL, McAtee N, Murphy RF, Balis FM, Cullen E, Chen AP, Hamilton JM, Steinberg SM, Quinn M, Sorensen JM, Arbuck SG, Lawrence D, Pang J, Allegra CJ: "A pilot study of gamma-1b-interferon in combination with fluorouracil, Leucovorin, and alpha-2a-interferon." *Clin Cancer Res* 1997 Jul;3(7): 1125-34.

JL Grem, N McAtee, RF Murphy, FM Balis, E Cullen, AP Chen, JM Hamilton, SM Steinberg, M Quinn, JM Sorensen, SG Arbuck, D Lawrence, J Pang, and CJ Allegra: "Phase I Study of Interferon-1b in Combination with Fluorouracil, Leucovorin, and Interferon-2a" *Clinical Cancer Research* 3: 1125-1134, 1997.

Grem JL, Steinberg SM, Chen AP, McAtee N, Cullen E, Hamilton JM, and Allegra CJ: "Carcinoembryonic Antigen as a Prognostic Factor in Advanced Colorectal Cancer" *Oncol Rep.*; 5 (3) 59-67, May-June 1998.

Shapiro JD, Harold N, Takimoto C, Hamilton JM, Vaughn D, Chen A, Steinberg SM, Liewehr D, Allegra C, Monahan B, Lash A, Grollman F, Flemming D, Brehan K, Johnston PG, Haller D, Quinn M, Morrison G, Grem JL: "A pilot study of interferon alpha-2a, fluorouracil, and Leucovorin given with granulocyte macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma" *Clin Cancer Res* 1999 Sep;5(9):2399-408.

Chen, Alice P.

16

Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ: "A Phase I study of raltitrexed, an antifolate Thymidylate Synthase inhibitor, in adult patients with advanced solid tumors." *Clin Cancer Res* 1999 Sep;5(9):2381-91.

Takimoto CH, Yee LK, Venzon KJ, Schuler B, Grollman F, Chabuk C, Hamilton JM, Chen AP, Allegra CJ, Grem JL: "High inter- and intra-patient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion." *Clin Cancer Res* 1999 Jun;5(6): 1347-52.

Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CJ, Schlom J: "A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors" *Immunother* 1999 Mar;22(2):155-65.

Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E: "Pharmacokinetics of thalidomide in an elderly prostate cancer population." *J Pharm Sci* 1999 Jan;88(1):121-5.

Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, Cottrell J, Guemel A, Llorens V, Hehman H, Ismail AS, Flemming D, Gosky DM, Hirota H, Berger SJ, Berger NA, Chen AP, Shapiro JD, Arbuck SG, Wright J, Hamilton JM, Allegra CJ, Grem JL: "Phase I and pharmacologic study of Irinotecan administered as a 96-hour infusion weekly to adult cancer patients." *J Clin Oncol* 2000 Feb;18(3):659-67.

Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM: "The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines" *Cancer Immunology, Immunotherapy* 2000 Nov 49(10):17-529.

Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E: "Pharmacokinetics of thalidomide in an elderly prostate cancer population" *Journal of Pharmaceutical Sciences* 2000 Jun 12; 88(1): 121 – 125.

Thomas RR, Dahut W, Harold N, Grem JL, Monahan BP, Liang M, Band RA, Cottree J, Llorens V, Smith JA, Corse W, Arbuck SG, Wright J, Chen AP, Shapiro JD, Hamilton JM, Allegra CJ, Takimoto CH: "A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients." *Cancer Chemother Pharmacol* 2001 Sep 48;(3):215-22.

Grem JL, Quinn M, Ismail AS, Takimoto CH, Lush R, Liewehr DJ, Steinberg SM, Balis FM, Chen AP, Monahan BP, Harold N, Corse W, Pang J, Murphy RF, Allegra CJ, Hamilton JM: "Pharmacokinetics and Pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion." *Cancer Chemother Pharmacol* 2001;47(2):117-25.

Chen, Alice P.

17

Grem JL, Harold N, Keith B, Chen AP, Kao V, Takimoto CH, Hamilton JM, Pang J, Pace M, Jasser GB, Quinn MG, Monahan: "A Phase I Pharmacologic and Pharmacodynamic study of Pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients" *Clin Cancer Res* 2002 Jul;8(7):2149-56.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicall D, Poole D, Scholm J, Michael Hamilton: "Phase I study of a vaccine using recombinant Vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer." *Prostate* 2002 Oct 1;53(2):109-17.

Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, and Murgo AJ: "Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies" *Clin Cancer Res* 2007 13: 5411-5417.

Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg S, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE and Doroshow JH: "Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice. *Molecular Interventions* 2007 7:325-334.

Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE and Doroshow JH: "Designing Phase 0 Cancer Clinical Trials" *Clinical Cancer Research* 2008 14, 3675-3682, June 15.

Shivaani K, Kinders R, Gutierrez M, Rubinstein L, Parchment R, Lawrence P, Ji J, Monks A, Pickeral O, DiPaolo T, Low J, Chen A, Murgo A, Collins J, Simpson M, Steinberg S, Yang S, Eliopoulos H, Giranda V, Gordon G, Horneffer Y, Juwara L, Yancey MA, Hollingshead M, Helman L, Wiltrout R, Tomaszewski J, Doroshow JH: "Phase 0 Clinical Trial of the Poly (ADP-ribose) Polymerase (PARP) Inhibitor ABT-888 in Patients with Advanced Malignancies" *JCO* 2009 27:2705-2711.

Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE, Doroshow JH: "Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas" *Cancer Biology & Therapy*: November 1, 2009, pp27 – 32.

Lacouture ME, Maitland ML, Segaert S, Setser A, Bara R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancy JE, Trotti A: "A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group" *Support Cancer Care* 2010 18 (4): 509-522.

Hussain M, Bradley DA, Daignault-Newton S, Ryan CJ, DiPaola RS, Smith DC, Small EJ, MD; Gross ME, Stein MN, Chen A, MD, Cooney KA, Pienta KJ, Mathew P, Escara-Wilke J, Al-Hawary SM, Keller ET, Doyle G: "Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the Prostate Cancer Clinical Trials Consortium." *Investigational New Drugs* 2011 Dec;29(6):1432-40.

Reinhardt S, Zhao M, Mnatsakanyan A, Xu L, Ricklis RM, Chen A, Karp JE, Rudek MA: "A Rapid and Sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS". *J Pharm Biom Analysis* 2010 52: 122-128.
Tarhini AA, Frankel P, Margolin K, Christensen S, Shipe-Spotloe J, Chen A, and John M. Kirkwood: "Phase II Study of Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin". *Clin Cancer Res.* 2011 Oct 15;17(20):6574-81.

Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshov JH: "Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. *Eur J Cancer* 2011 May; 47(7): 997-1005.

Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Liao CY, Hartley JA, Berlin JD, Rothenberg ML: "Phase I, Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in advanced solid tumors". *Clin Cancer Res.* 2011 Jun 1;17(11):3794-802.

Hossain A, Chen A, Ivy P, Lenihan DJ, Kaltman J, Taddei-Peters W, Remick SC: "The Importance of Clinical Grading of Heart Failure and Other Cardiac Toxicities During Chemotherapy: Updating the Common Terminology Criteria for Clinical Trial Reporting". *Heart Failure Clin* 2011 7:373-384.

Weil M, Chen A: PARP Inhibitors in Ovarian and Breast Cancer. *Current Problems in Cancer, Current Problems in Cancer, Curr Probl Cancer* 2011 35(1): 7-50, 2011. (Invited manuscript)

de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, DeAngelis LM, Yung WKA, Chen A, Prados MD, and Wen PY: "Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study". *JCO* Jul 2011; 29(19): 2689-2695.

de Groot JF, Piao Y, Tran H, Gilbert M, Wu, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WKA, Prados M, Wen PY, Heymach JV: Myeloid Biomarkers Predict Glioblastoma Response to Anti-Vascular Endothelial Growth Factor Therapy with Aflibercept. *Clinical Cancer Res* 2011 July 15; 17:4872-81.

Chen A: PARP Inhibitors: Its role in Cancer Treatment. *Chin J Cancer* 2011 30:1-9. (Invited manuscript)

Chen, Alice P.

19

Speranza G, Gutierrez ME, Kummar S, Strong JM, Parker RJ, Collins J, Yu Y, Cao L, Murgo AJ, Doroshow JH, Chen A: "Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors". *Cancer Chem Pharm Online* first 30 July 2011.

Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Pachement RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH: "Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas" *Cancer Res* 2011 Sept 1; 71(17); 5626–34.

Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, Chen AP, Pommier Y, Doroshow JH, Yang SX: "Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent". *Cell Cycle* 2011 Dec 1; 10:23, 1-9.

Kummar S, Ji J, Morgan R, Lenz H, Puhalla SL, Belani CP, Gandara D, Allen D, Kiesel B, Beumer JH, Newman E, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders R, Parchment RE, Tomaszewski JE, Doroshow JH: "A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas". *Clinical Cancer Res* 18:1726-34, 2012.

Park SR, Chen AP: "Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Cancer Treatment". *Hematol Oncol Clin N Am* 26,649-670, 2012. (Invited manuscript)

Chen AP¹, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, Lacouture ME: Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. *J Am Acad Dermatol*. 2012 Nov;67(5):1025-39.

Nair A, Chen AP: "The Maze of PARP Inhibitors in Ovarian Cancer". *Oncology (Williston Par)* Feb;26(2):136-7, 141-2, 2012. (Invited manuscript)

Bender JG, Blaney SM, Borinstein S, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, and Park JR: A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. *Clin Cancer Res* 18(18): 5081-9, Sep 15 2012.

Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MK, Lourenco L, Wang L, Chen A, Moore JM: A Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer: A study of the Princess Margaret Hospital Phase II Consortium *Clin Cancer Res* 18(21): 6023-31, Nov 1 2012.

Chen, Alice P.

20

Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH: Advances in using PARP inhibitors to treat cancer. *BMC Medicine* 10:25, 2012.

Do K, Chen A: Molecular Pathways: Targeting PARP in Cancer Treatment. *Clin Cancer Res* 19(5): 977-84, 2012. (Invited manuscript)

Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, deGroot J: Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. *Targeted Oncol*, 8(2):117-25, 2013.

Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Pau DB, Gagne J, Rogak L, Sit L, Viswanath V, Schrag D, Basch E, the NCI PRO- Study Group: Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Qual Life Res* 23(1):257-69, Feb 2014.

Kummar S, Gutierrez ME, Anderson LW, Kiecker R Jr., Chen A, Murgu AJ, Doroshow JH, Collins JM: Pharmacogenetically-Driven Patient Selection for a First-in-Human Phase I Trial of Batracylin in Patients with Advanced Solid Tumors and Lymphomas. *Cancer Chemo Pharm* 72(4):917-23, 2013.

Su JM, Thompson PA, Adesina A, Li XN, Kilburn LB, Onar-Thomas A, Kocak M, Chyla B, McKeegan EM, Warren KE, Goldman S, Pollack I, Fouladi M, Chen A, Giranda VL, Boyett JM, Kun LE, Blaney S: A Phase I Trial of Veliparib (ABT-888) and Temozolomide in Children with Recurrent Central Nervous System Tumors: A Pediatric Brain Tumor Consortium Report. *Neuro-oncology*, June 7, 2014.

Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch J, Takebe N, Malik S, McShane L, Korn E, Williams M, Staudt L, Doroshow J: National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network. 2014 ASCO Educational Book.

Jeong W, Rapisarda A, Park SR, Kinders R, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S: Pilot Trial of EZN-2968, an Antisense Oligonucleotide Inhibitor of Hypoxia-inducible factor-1 alpha (HIF-1a) in Patients with Refractory Solid Tumors. *Cancer Chemother Pharmacol* 73:343-348, 2014.

Owonikoko TK, Zhang G, Deng X, Rossi MR, Doho GH, Chen Z, Switchenko JM, Kim S, Strychor S, Christner SM, Li C, Yue P, Chen A, Beumer J, Sica GL, Kowalski J, Ramalingam SS, Khuri FR, Sun SY: Poly (ADP) ribose polymerase (PARP) enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. *Cancer Medicine* Dec; 3(6): 1579-94, 2014.

Jeong W, Park SR, Rapisarda A, Fer N, Kinders RJ, Chen A, Melillo G, TurkbeySteinberg SM, Choyke P, Doroshow JH, Kummar S: Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. *Invest New Drugs* (2014) 32:340–346.

Reiss KA, Herman JM, ahurak ML, Brade A, Dawson L, Scardina A, Joffe C, Petito E, Hacker-Preitz A, Kinders R, Wang L, Chen A, Temkin SM, Horiba N, Siu LL, Azad NA: A Phase I Study of Veliparib (ABT 888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis. *Clin Can Res* 21(1); 68–76, 2014.

Kummar S, Williams M, Lih CJ, Polley EC, Chen AP, Rubinstein LV, Zhao Y, Simon RM, Conley BA, Doroshow JH: Application of Molecular Profiling in Clinical Trials for Refractory Cancers. *JNCI* 107(4): 1-6, 2015.

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Ducek AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner PB, Denicoff A, St. Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D: Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *JNCI* 106(9): 1-11, 2014.

Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero V, Morgan RJ, Sabo P, Youn A, Chen AP, Ji JP, Allen DE Lih CJ, Mehaffey MG, Walsh WD, McGregor PM, Steinberg SM, Williams PM, Kinders RJ, Duan W, Conley BA, Simon RM, Doroshow JH: Randomized Trial of Cyclophosphamide and the oral Poly (ADP-Ribose) Polymerase Inhibitor Veliparib in Patients with Advanced High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. *Clin Cancer Res* 21(7): 1574-82, 2015.

Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders RJ, Collins J, Chen A, Doroshow JH, Kummar S: Phase I Study of Single Agent AZD1775 (MK-1775), a WEE1 Kinase Inhibitor, in Patients with Refractory Solid Tumors. *JCO* Oct 20;33(30):3409-15, 2015.

Do K, Speranza G, Chang LC, Polley EC, Bishop R, Zhu W, Trepel JB, Lee S, Lee MJ, Kinders RJ, Phillips L, Collins J, Lyons J, Jeong W, Antony R, Chen AP, Neckers L, Doroshow JH, Kummar S: Phase I Study of the Heat Shock Protein 90 (Hsp90) Inhibitor Onalespib (AT13387) Administered on a Daily for 2 Consecutive Days per Week Dosing Schedule in Patients with Advanced Solid Tumors. *Invest New Drug* Aug;33(4):921-30, 2015.

Do K, O'Sullivan-Coyne G, Chen A: An Overview of the NCI Precision Medicine Trials – MATCH and M-PACT. *Chin Clin Oncol* 4(3), 31-9, 2015.

Chen, Alice P.

22

Coleman R, Sill MW, Bell-McGuinn K, Aghajanian CA, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM: A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG Oncology/Gynecologic Oncology Group study. *GYN Oncol* 137(3): 386-391, 2015.

Flaherty KT, Chen A, O'Dwyer P, Hamilton S, Williams M, Conley B: The NCI MATCH Trial. *Clinical Pharmacology & Therapeutics* (Invited-in progress). 2015.

Zhao Y, Polley E, Li MCh, Lih CJ, Palmisano A, Sims D, Rubeinstein L, Conley B, Chen A, Williams PM, Kummar S, Doroshov, Simon R: GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials. *Cancer Informatics* 14(S2): 45-55, 2015.

Villalona-Calero, MA, Duan, W, Zhao W, Shilo, K, Schaaf LJ, Thurmond J, Westman JA, Marshall JA, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C: Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors with Functional Deficiency in Homologous Recombination Repair *JNCI* 108 (7), 2015.

Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen DE, O'SullivanCoyne G, Steinberg SM, Doroshov: Randomized Phase II Trial of Cyclophosphamide and the Oral Poly (ADP-ribose) Polymerase Inhibitor Veliparib in Patients with Recurrent, Advanced Triple-Negative Breast Cancer. *Investigational New Drugs* 21(7) 1575-82, 2015.

Lih CJ, Sims D, Harrington R, Polley E, Zhao YD, Mehaffey M, Forbes T, Das B, Walsh W, Datta V, Simon R, Conley B, Chen A, Kummar S, Doroshov JH, Williams M: Analytical validation of a targeted Next Generation Sequencing Assay for the Molecular Profiling based Assignment of Cancer Therapy Clinical Trial. *J Mol Diagn* 18(1):51-67, 2016.

Kummar S, Do K, O'Sullivan Coyne G, Chen A, Ji J, Rubinstein L, Doroshov JH: Establishing Proof of Mechanism: Assessing Target Modulation in Early-Phase Clinical Trials. *Semin Oncol* 43(4) 446-452, 2016.

Ferry-Galow KV¹, Makhlof HR², Wilsker DF³, Lawrence SM³, Pfister TD³, Marrero AM⁴, Bigelow KM⁵, Yutzy WH³, Ji JJ³, Butcher DO⁶, Gouker BA⁶, Kummar S⁷, Chen AP⁸, Kinders RJ³, Parchment RE³, Doroshov JH⁹. The Root Causes of Assay Failure. *Semin Oncol* 43(4):484-91, 2016.

Wang L, Balasubramanian P, Chen AP, Kummar S, Evrard YA, Kinders RJ: Promise and Limits of the CellSearch Platform for Evaluating Pharmacodynamics in Circulating Tumor Cells. *Semin Oncol* 43(4): 464-475, 2016.

Lih CJ, Chen AP: "N of 2 Responders with LMNA-NTRK1". *JNCI* 208(1), 2016.

LoRusso PM, Li J, Burger A, Heibrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Volanski A, Marrero A, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI: Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors. *Clin Cancer Res* 22(13): 3227-37, 2016.

Meehan RS, Chen AP: New treatment option for ovarian cancer: PARP inhibitors. *Gynecologic Oncol Res Prac* 3(3) 1-8, 2016.

Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH: Clinical and Pharmacologic Evaluation of Two Dosing Schedules of Indotecan (LMP 400), a Novel Indenoisoquinoline, in Patients with Advanced Solid Tumors. *Cancer Chemother Pharmacol* 78: 73-81, 2016.

O'Sullivan Coyne G, Chen A, Kummar S: Delivering on the promise: PARP inhibition as targeted anticancer therapy. *Curr Opin Oncol* Nov 27(6): 475-481, 2016.

Pratz KW, Rudek MA, Gojo I, Litzow M, McDevitt MA, Ji J, Karnitz L, Herman J, Kidners R, Rickles R, Smith BD, Gore S, Carraway HE, Showel M, Levis MJ, Gladstone DE, Rosner G, Chen A, Kaufmann SH, Karp JE: A Phase I dose escalation study of the combination of topotecan, carboplatin and the poly-ADP ribose polymerase inhibitor (PARP) veliparib (ABT-888) in relapsed or refractory acute myelogenous leukemia or aggressive myeloproliferative neoplasms. *Clinical Cancer Res* 23(4): 899-907, 2016.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern A, Gladstone DE, Ji J, Wang L, Kidners RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman J, Karnitz LM, Kaufman SH, Chen A, Karp JE: A phase I study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. *Clin Cancer Res* Aug 8, 2016.

Lin FI, Gonzalez EM, Kummar S, Do K, Shih J, Adler S, Kurdziel, Ton A, Turkbey B, Jacombs PM, Bhattacharyya, Chen AP, Collins JM, Doroshow JH, Choyke PL, Lindenberg ML: Utility of ¹⁸F-fluoroestradiol (¹⁸F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therap. *European Journal of Nuclear Medicine and Molecular Imaging*, 1-9, 2016.

Ferry-Galow KV, Makhlof HR, Wilsker DF, Lawrence SM, pfister TD, Marrero AM, Bigelow KM, Yutzy WH, Ji JJ, Butcher DO, Gouker BA, Kummar S, Chen AP, Kinders RJ, Parchment RE, Doroshow JH: Chapter 7: The root causes of pharmacodynamics assay failure. *Sem Oncol, Seminars of Oncology, Pharmacodynamics in Cancer Drug Development*. *Sem Oncol* 43 (4): 484-491, 2016.

Kummar S, Do K, Chen A, Ji J, Rubinstein L, Doroshow J: Chapter 3: Assessing Target Modulation in Early-Phase Clinical Trials. *Seminars of Oncology, Pharmacodynamics in Cancer Drug Development*. *Sem Oncol* 43(4): 446-452, 2016.

Wang L, Balasubramanian P, Chen AP, Kummar S, Evrard YA, Kinders R: Chapter 5: Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells. *Seminars of Oncology, Pharmacodynamics in Cancer Drug Development*. *Sem Oncol* 43(4): 464-475, 2016.

Meehan R, Chen Alice, Doroshow JH: Role of Adaptive Randomization in Developing Novel Therapies for Patients with Breast Cancer. *Tran Cancer Res* 5(Suppl6): S1119-1122, 2016.

O'Sullivan-Coyne, G, Chen A, Meehan R, Doroshow JH: PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. *Drugs* Jan 11, 2016.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF: The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma. *Clin Can Res* 2017.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vajdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Gerry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN: Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline *BRCA1*- or *BRCA2*-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. *Clin Can Res* 23(15): 4066-4076, 2017.

Ji J, Zhang Y, Redon CE, Reinhold WC, Chen AP, Fogli LK, Holbeck SL, Parchment RE, Hollingshead M, Tomaszewski JE, Pommier Y, Doroshow JH, Bonner WM: Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. *PLoS ONE* 12(2): 118, 2017.

Nayak L, deGroot J, Wefel JS, Cloughesy T, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AWK, Fisher J, Ye X, Lamborn K, Chen A, Grossman S, Prados M, Wen PY: Phase I Trial of Aflibercept (VEGF Trap) with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with High-Grade Gliomas. *J Neuro-Onc* 132 (1): 181-188, 2017.

Seymour L, Bogaaerts J, Perrone A, Ford R, Schwart L, Mandrakar S, Lin N, Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra O, Shankar L, Wolchok J, Ballinger M, Caramelia C, de Vries E: iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. *Lancet Onc* 18(3): e143-152, 2017.

O'Sullivan Coyne G, Takebe N, Chen AP: Defining precision: The Precision Medicine Initiative Trials NCI-MPACT and NCI-MATCH. *Curr Probl Cancer*, 41(3), 182-193, 2017.

Herman JM, Armstron D, Zahurak M, Fyles A, Brade A, Milosevic M, Dawson LA, Scardina A, Fischer P, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Stayner L, Siu LL, Azad NS: A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. *Gyn Onco* 144 (3): 486-490, 2017.

Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, Piekarz RL, Sukari AW, Chao J, Pilat MJ, Smith DW, Casetta L, Boerner SA, Chen A, Lenkiewicz E, Malasi S, LoRusso PM: A phase 2 Study of Vorinostat in Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma. *Oncotarget* 8(20): 32918-32929, 2017.

Hendrickson AEW, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred J, Lensing J, Chen A, Ji J, Zang Y, Erlichman C, Haluska P, Kaufmann SH: A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. *Clin Can Res* DOI: 10.1158/1078-0432.CCR-17-1590.

O'Sullivan Coyne G, Woodring T, Lee C, Chen AP#, Kong HH: Hidradenitis suppurativa-like lesions associated with pharmacologic inhibition of gamma-secretase. *J Inv Derm* (accepted).

Pietanza M, Waqar S, Krug L, Dowlati A, Hann C, Chiappori A, Owonikoko T, Woo K, Cardnell R, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman E, Wistuba I, Chen A, Fleisher M, Heymatch J, Kris M, Rudin C, Byers L: A Phase II Study Comparing Veliparib, a PARP Inhibitor, versus Placebo with Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer. *Cancer Discover*, 2017 (submitted).

Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Bolleran J, Kiesel BF, Czambel RK, Carneiro BA, Kontopodis E, Hershberger P, Rashid M, Giranda V, Chen A, Chu E, Beumer JH. Phase I Study of Veliparib in Combination with Gemcitabine. *Can Chem Pharm* 80(3): 631-643, 2017..

Hendrickson AW, Menefee M, Hartmann L, Long H, Northfelt D, Reid J, Boakye-Agyeman F, Kayode O, Flatten K, Harrell M, Swisher E, Poirer G, Satele D, Allred J, Lensing J, Chen A, Ji J, Zhand Y, Erlichman C, Haluska P, Kaufmann: A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. *Clin Can Res* DOI: 10.1158/1078-0432.CCR-17-1590.

Anampa J, Chen A, Wright J, Patel M, Pellegrino C, Fehn K, Sparao JA, Andreopoulou E: Phase I trial of veliparib, a poly ADP ribose polymerase inhibitor, plus metronomic cyclophosphamide in metastatic HER2 negative breast cancer. *Clin Breast Can* doi.org/10.1016/j.clbc.2017.08.013.

Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stradler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan ME, Salo-Mullen EE, Do RKG, Chen AP,

Chen, Alice P.

26

Yu KH, Tang LH, O'Reilly EM: Phase II Trial of Veliparib in Patients with Previously-Treated BRCA or PALB2-Mutated Pancreas Ductal Adenocarcinoma. *Eur J Can* 89: 19-26, 2018.

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler Z, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP: Phase I Trial Evaluating Cisplatin, Gemcitabine and Veliparib in Two Patient Cohorts: Germline-BRCA Mutation Carriers and BRCA Wild-Type Pancreas Ductal Adenocarcinoma. *Cancer* 124: 1374-82, 2018.

CHAPTERS

Weil M, Kummar S, Doroshow JH, Chen AP*: "BRCA Mutations and PARP Inhibitors" in Handbook of Therapeutic Biomarkers in Cancer Pan Stanford Publishing, Dec 2012.

Chen A*, Acharya A, Setser A: "Grading Dermatologic Adverse Events on Clinical Trials using CTCAEv4". Dermatological Principles and Practice in Oncology, Chapter 5, 2014.

Chen A*, Mitchell SA, Minasian LM, St. Germain D: "Incorporating Patient-Reported Outcomes into Early-Phase Trials: New Tools" in Novel Designs of Early Phase Trials for Cancer, Chapter 12, 2017.

*Corresponding author

#Co-senior author

ABBREVIATED ABSTRACTS (2016-):

Gojo I, Beumer JH, Pratz KW, Ji J, Wang L, Rudek MA, McDevitt M, Baer MR, Blackford A, Smith BD, Gore S, Carraway HE, Showel M, Levis M, Dezern A, Gladstone D, Jain T, Greer J, Pouquet M, Ali-Walbi I, Herman J, Poh W, Karnitz LM, Kaufmann SH, Chen A, Karp JE: A Phase 1 Study of the PARP Inhibitor Veliparib in combination with Temozolomide in Acute Leukemias. ASH 1361, 2015 (poster).

Conley BA, Gray R, Chen A, O'Dwyer PJ, Arteaga CL, Coffey B, Patton D, Li, S, McShane LM, Rubinstine L, Comis R, Abrams J, Williams PM, Lih CJ, Hamilton S, Mitchell E, Zwiebel J, Flaherty KT: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis. AACR #CT101, 2016 (Poster).

Srivastava AK, Govindharajulu J, Park S, Vavas T, Ferry-Gallow K, Kinders RJ, Lee Y, Bottaro DP, Wright J, Hollingshead MG, Tomaszewski JE, Chen A, Parchment RE, Kummar S, Doroshow JH: Pazopanib Suppresses MET Signaling in Patients with Refractory Advanced Solid Tumors. *J Clin Oncol* 34, 2016 (suppl; abstr 2553) (Poster).

Chen, Alice P.

27

Reiss KA, Herman JM, Zahurak M, Fyles AW, Milosevic MF, Scardina A, Joffe C, Petito E, Hacker-Prietz A, Chen AP, Temkin SM, Horiba N, Kinders RJ, Wang L, Stayner L, Azad NS: Final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. *J Clin Oncol* 34, 2016 (suppl; abstr 2584) (Poster).

O'Sullivan GH, Kummar S, Do KT, Choyke PL, Turkbey B, Polley E, Horneffer Y, Juwara L, Vilimas RJ, Meehan RS, Helman LJ, Doroshow JH, Chen AP: Activity of PF-03084014 in adults with Desmoid tumors/Aggressive Fibromatosis. *J Clin Oncol* 34, 2016 (suppl; abstr 11028) (Merit award-O'Sullivan, Poster)

Meehan RS, Chen AP, O'Sullivan GH, Collins JM, Kummar S, Anderson L, Ishii K, Zlott J, Rubinstein L, Horneffer Y, Juwara L, Jeong W, Takebe N, Kinders RJ, Parchment RE, Doroshow JH: A Phase 1 Trial of TRC102 (methoxyamine HCl) with Temozolomide (TMZ) in Patients with Solid Tumors and Lymphomas. *J Clin Oncol* 34, 2016 (suppl; abstr 2556) (Merit Award-Meehan, Poster).

Pietanza MC, Krug LM, Wagar SN, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo K, Bensman Y, Hurtado B, Fujimoto J, Wistuba II, Tavis WD, Chen AP, Heymach J, Kris MG, Fleisher M, Rudin CM, Byers LA: A Multi-Center, Randomized, Double-Blind Phase II Study Comparing Temozolomide (TMZ) plus either Veliparib (ABT-888), a PARP Inhibitor, or Placebo as 2nd or 3rd-Line Therapy for Patients (Pts) with Relapsed Small Cell Lung Cancers (SCLCs). *J Clin Oncol* 34, 2016 (suppl; abstr 8512) (Poster).

Chen AP, Williams M, Kummar S, Lih CJ, Datta V, Polley E, Zhao Y, Rubinstein L, O'Sullivan GH, Meehan RS, Moore N, Sharon E, Palmisano A, Sims D, Harrington R, Bouk C, Harper KV, Simon R, Conley BA, Doroshow JH: Feasibility of Molecular Profiling based Assignment of Cancer Treatment (MPACT), a Randomized NCI Precision Medicine Study. *J Clin Oncol* 34, 2016 (suppl; abstr 2539) (Poster).

Conley, B, Chen A, et al: "NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial". *J Clin Oncol* 34, 2016 (suppl; abstr TPS2606) (Poster)

O'Sullivan Coyne G, Chen AP, Kummar S, Collins JM, Meehan RS, Suto MJ, Rubinstein L, Kinders RJ, Moore N, Parchment RE, Horneffer Y, Juwara L, Streicher H, Piekarz R, Difilippantonio MJ, Doroshow JH: First-in-human trial of 4'-thio-2'-deoxycytidine (TdCyd) in patients with advanced solid tumors. *ESMO*, 2016 (Poster).

Chen A, Conley B, Hamilton S, Williams M, O'Dwyer PJ, Arteaga C, Gray R, McShane L, Li S, Rubinstein L, Patton D, Zhang J, Zwiebel J, Mitchell E, Smith ML, Dragaud, Little RF, Comis R, Abrams J, Flaherty K: NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: A novel public-private partnership. *ENA* 2016 (Poster)

O'Sullivan Coyne G, Chen AP, Kummar S, Meehan RS, Collins J, Zlott J, Kelly K, Lenz HJ, Newman EM, Morgan R, Juwara L, Eiseman J, Beumer JH, Tomaszewski J, Doroshow J: Phase I trial of oral 5-fluoro-2'-deoxycytidine with oral tetrahydrouridine in patients with advanced solid tumors". ENA 2016 (Poster)

Meehan RS, O'Sullivan Coyne GH, Kummar S, Zlott J, Juwara L, Streicher H, Sharon E, Harris P, Doroshow JH, Chen AP: Phase I Trial of Ganetespib and ziv-aflibercept in patients with advanced gastrointestinal carcinomas, non-squamous non-small cell lung carcinomas, urothelial carcinomas, and sarcomas. ENA 2016 (poster).

Ferry-Galow K, Makhlof H, Kinders R, Chen A, Doroshow JH, Parchment RE: Suitability of post-diagnostic core needle tumor biopsies for correlative studies of molecular drug action (pharmacodynamics) ENA 2016 (Poster).

Meehan R, O'Sullivan Coyne G, Kummar S, Lamin J, Zlott J, Rubinstien L, Sharon E, Takebe N, Wright J, Doroshow J, Chen A: A Phase II Trial of cabozantinib (XL-184) in metastatic refractory soft tissue sarcoma. TAT, 2017 (poster).

Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Muzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, McDermott D, Chen A, Lara PN, Kirkwood, JM: NCI 8628 - A Randomized Phase II Study of Ziv-aflibercept (Z) and High Dose Interleukin-2 (IL-2) or IL-2 alone for Inoperable Stage III or IV Melanoma: Efficacy and Biomarker Study. AACR 2017 (poster).

Meehan R, Chen AP, O'Sullivan Coyne G, Kummar S, Ji J, Vilimas R, Juwara L, Kinders RJ, Ferry-Galow K, Wilsker D, Zhang Y, Dull AB, Navas T, Wang L, Parchment RE, Doroshow JH: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations. AACR 2017 (poster).

Woodring T, O'Sullivan-Coyne G, Chen AP, Kong HH: Dermatologic toxicity associated with chronic gamma-secretase inhibitor treatment for desmoid tumor. JID 137(5, suppl 1), S52. (Poster)

Navas T, Srivastava AK, Ferry-Galow K, Makhlof H, Chuaqui R, Kinders RJ, Bottaro DP, Chen A, Parchment RE, Kummar S, Doroshow JH: Evidence of Pazopanib-Induced Epithelial-Mesenchymal Transition (EMT) in Human Tumors. ASCO 2017. (poster)

Litière S, Isaac G, de Vries EG, Bogaerts J, Chen AP, Dancey J, Ford R, Gwyther SJ, Hoekstra OS, Huang E, Lin NU, Liu Y, Mandrekar SJ, Schwartz LH, Shankar L, Therasse P, Seymour L: RECIST 1.1 validated not only for cytotoxic agents but also for targeted cancer agents (TCA): results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database. JCO 35, suppl abstr 2534, 2017. (poster)

Ferry-Galow K, Makhlof H, Wood B, Levy E, Krishnasamy V, Chang R, O'Sullivan Coyne G, Meehan R, Kinders R, Parchment RE, Doroshow JH, Chen A: Suitability Factors of Core Needle Biopsies for Pharmacodynamic (PD) Studies. JCO 35 suppl abstr 2540, 2017. (poster)

Chen, Alice P.

29

O'Sullivan Coyne GH, Kummar S, Meehan RS, Streicher H, Takebe N, Sharon E, Conley BA, Harris L, Collins JM, Moore N, Juwara L, Rubinstein L, Quinn MF, Pommier Y, Cushman M, Doroshow JH, Chen AP: Phase I Study of Indenoisoquinolines LMP776 in Adults with Relapsed Solid Tumors and Lymphomas. JCO 35 suppl abstr 2558, 2017.(poster)

O'Sullivan Coyne GH, Kummar S, Meehan RS, Juwara L, Piekarz R, Sharon E, Streicher H, Conley BA, Takebe N, Harris L, Doyle A, Quinn MF, Rubinstein L, Wilsker D, Kinders RJ, Parchment RE, Levy EB, Doroshow JH, Chen AP: Phase I Trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors. JCO 35, suppl abstr TPS2609, 2017. (Poster)

Meehan RS, O'Sullivan Coyne GH, Kummar S, Collins JM, Anderson L, Zlott J, Juwara L, Takebe N, Piekarz R, Streicher H, Sharon E, Conley BA, Rubinstein L, Wilsker D, Dull AB, Ferry-Galow KV, Kinders RJ, Parchment RE, Doroshow HJH, Chen AP: A Phase I Trial of TRC102 (methoxyamine HCl) with Temozolomide (TMZ) in Patients with Solid Tumors and Lymphomas. JCO 35, suppl abstr 2517, 2017.(Poster Discussion)

Datta V, Harrington R, Robinson H, Sims D, McDermott S, Karlovich C, Chen A, Flaherty K, Hong D, Kwak E, Catenacci D, Hamilton S, Conley B, Routbort M, Sklar J, Iafrate J, Williams M: Low Level METex14 Skipping Is Observed at Low Frequencies in Patients with Solid Tumors from the NCI-MATCH Clinical Trial. AMP 2017. (Poster Presentation)

Harris L, Chen A, O'Dwyer P, Flaherty K, Hamilton S, McShane L, Gray R, Li S, Mitchell E, Dragaud D, Williams M, Sklar J, Iafrate AJ, Patton D, Little RF, Zweibel J, Abrams J, Doroshow J, Conley B: Update on the "NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131)" precision medicine trial. EORTC 2017, #B80. (Poster Presentation).

Conley BA, Hamilton SR, Li S, Gray RJ, Patton DR, O'Dwyer PJ, Comis RL, Abrams JS, Azad NS, Overman MJ, Schoenfeld JD, Williams PM, Tricoli JV, Dragaud DM, Sharon E, Streicher HZ, Harris LN, Chen AP, Flaherty K: Prevalence of Mismatch Repair Deficiency (dMMR) in the NCI Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) Population. EORTC 2017. (Poster Presentation).

Navas T, Srivastava AK, Cutuli F, Ferry-Galow K, Makhlof H, Chuaqui R, Kinders RJ, Bottaro DP, Chen AP, Parchment RE, Kummar S, Doroshow JH: Evidence of pazopanib-induced Epithelial-Mesenchymal Transition (EMT) in human tumors. EORTC 2017 (Poster Presentation).

Ghias MH, Woodring T, O'Sullivan Coyne G, Chen AP, Kong HH, and Lowes MA: Presentation Title: Gamma-secretase inhibitors may cause Hidradenitis Suppurativa-like lesions. SHSA, 2017 (Poster).

O'Sullivan Coyne G, Kummar S, Takebe N, Do KT, Meehan R, Piekarz R, Zlott J, Juwara L, Quinn M, Sharon E, Streicher H, Rubinstein L, Levin C, Doroshow JH, Chen AP: Single Agent AZD1775, a Wee1 Inhibitor, Shows Activity in *BRC1* Deficient Patients, Mol Can Therapeutics 17(1 suppl), ab B079, 2018.

Azad N, Overman M, Gray R, Schoenfeld J, Arteaga C, Coffey B, Patton D, Li S, McShane L, Rubenstein L, Harris L, Comis R, Abrams J, Williams PM, Mitchell E, Zweibel J, Sharon E, Streicher H, O'Dwyer PJ, Hamilton S, Conley B, Chen AP, Flaherty K: Nivolumab in mismatch repair deficient (MMRd) cancers: NCI MATCH Trial (Molecular Analysis for Therapy Choice) arm Z1D preliminary results. SITC 2017, LBA 37.

Chen A, O'Sullivan Coyne G, Meehan R, Kummar S, Juwara L, Zlott J, Rubinstein L, Piekarcz R, Quinn M, Takebe N, Wright J, Doroshow J: A Phase 2 Trial of Cabozantinib (XL 184) in Metastatic Refractory Soft Tissue Sarcoma. CTOS, 2017. (Poster Oral Presentation)

Laruing J, Grilley-Olsen J, Jegede O, Chen A, Flaherty KT, Conley BA, O'Dwyer P, Williams M, Hamilton S, Harris L, McShane L, Rubinstein L, Gray R, Krop I: Results from Molecular Analysis for Therapy Choice (MATCH) Arm I: Taselisib for PIK3CA-mutated tumors. ASCO 2018. (Oral Presentation).

Jhaveri KL, Makker V, Wang XV, Chen AP, Flaherty K, Conley BA, O'Dwyer PJ, Williams PM, Hamilton SR, Harris L, McShane L, Rubinstein L, Gray RJ, Li S, Mitchell EP, Patton D, Moscow J, Zwiebel J, Arteaga CL, Luoh SW: Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) - Molecular Analysis for Therapy Choice (MATCH) trial. ASCO 2018, (oral presentation).

O'Sullivan Coyne G, Do KT, Kummar S, Takebe N, Quinn M, Piha-Paul S, Bruns A, Juwara L, Sharon E, Piekarcz R, Streicher H, Rubinstein L, Wilsker D, Kinders R, Parchment R, Levy E, Doyle LA, Doroshow JH, Chen AP: Phase I Trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors. ASCO 2018 (poster).

O'Sullivan Coyne G, Conlon K, Takebe N, Streicher H, Parchment R, Kinders R, Quinn M, Bruns A, Sharon E, Doroshow J, Waldmann T, Chen A: Phase I Study of Recombinant Interleukin 15 in Combination with Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers. ASCO 2018 (poster).

Glod J, Cohen JW, Widemann BC, Goodwin A, Derdak J, Dombi E, Kapustina O, Steinberg S, O'Sullivan-Coyne G, Kummar S, Chen AP: Cediranib Phase II Study in children with metastatic alveolar soft part sarcoma (ASPS). ASCO 2018. (Poster)

Takebe N, O'Sullivan Coyne G, Kummar S, Do K, Bruns A, Juwara L, Quinn M, Harris L, Piekarcz R, Prindiville S, Sharon E, Streicher H, Mugundy G, Ji J, Wilsker D, Kinders RJ, Rubinstein L, Doroshow JH, Chen AP: Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775. ASCO 2018. (Poster).

Takebe N, O'Sullivan Coyne G, Kummar S, Reid JM, Lindenberg M, Piekarcz R, Harris L, Juwara L, Quinn M, Moore N, Choyke P, Mena E, Lin F, Streicher H, Covey J, Collins J, Doroshow JH, Chen A: Phase I Trial of Z-Endoxifen with Estrogen Receptor Imaging in Adults with Advanced Hormone Receptor-Positive Solid Tumors Including Desmoid and Gynecologic Tumors. ASCO 2018 (Poster Discussion).

Chen, Alice P.

31

Chae YK, Vaklavas C, Cheng HH, Hong F, Harris L, Michell E, Zwiebel J, Rubinstein L, McShane L, Gray R, Li S, Ivy P, Ansher S, Hamilton S, Williams M, Patton D, Tricoli J, Arteaga C, Conely B, O'Dwyer P, Chen A, Flaherty K: Molecular Analysis for Therapy Choice (MATCH) Arm W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway. ASCO, 2018 (oral presentation).

ABBREVIATED PRESENTATIONS (2016-)

“NCI MATCH”

New PI orientation

January 13, 2016

Webinar

“NCI MATCH”

New PI orientation

January 20, 2016

Webinar

NCI MATCH Pharma meeting

Participant

January 21, 2016

webinar

“NCI Precision Medicine”

Pain and Paliative Didactic Session

February 3 2016

Bethesda

“Optimizing Study Outcomes, Stratification & Enrichment Approaches in Oncology”

American Society for Clinical Pharmacology and Therapeutics

Challenges in Global Drug Development and Regulation Pre-Conference

March 8, 2016

San Diego

“Personalized cancer drug development program at NCI”

Pharmacogenomics and Personalized Medicine Course

Duke University

April 6, 2016

Webinar

“Lessons Learned from Master Protocols”

*Accelerating Anticancer Agent Development
And Validation Workshop*

In-Depth Panelist

May 5, 2016

Bethesda

Chen, Alice P.

32

“NCI MATCH: Future Directions”

Presenter

ECOG ACRIN Annual Meeting

May 14, 2016

Boston

“Precision Medicine Initiatives at the NCI”

Presenter

Translational Oncology Program at Stanford

May 19, 2016

Stanford, CA

“NCI MATCH”

Presenter

NCI Advocacy Webinar

May 25, 2016

“Master Protocol Design”

Presenter

The State of Science Cancer CAM Therapeutics Workshop

May 26, 2016

Bethesda

“Cediranib Trials in DTC”

Collaborator Meeting with AZ at ASCO

Chicago

June 4, 2016

“CTCAE v.5.0

Meet the Expert

ASCO

June 4, 2016

“Interim Analysis of early NCI-MATCH data”

NCI-MATCH Pharmaceutical Collaborators Meeting

ASCO

June 5, 2016

“NCI-MATCH overview and interim analysis results”

MATCH Sub-protocol Meeting

ASCO

June 6, 2016

Chen, Alice P.

33

“NCI Match”

Meet the Expert

ASCO

June 6, 2016

“NCI MATCH subprotocol PI orientation”

Copanlisib PI Orientation

Webinar

June 8, 2016

“Desmoid”

6th Element Scientific Advisory Board Meeting

July 8, 2016

“Developmental Therapeutics Clinic”

Walter Reed NMMC

July 8, 2016

“Exceptional Responder and NCI MATCH”

9th annual Cancer Molecular Therapeutics Research Association Meeting

July 20, 2016

Seattle, WA

Pfizer GSI Clinical Trial Design Working Session

September 9, 2016

Bethesda, MD

“NCI Initiative in Precision Medicine”

2016 Sino-American Forum on Cancer Precision Medicine

September 20, 2016

Beijing, China

“NCI Initiatives in Precision Medicine: NCI MATCH”

2016 Chinese Society of Clinical Oncology

September 22, 2016

Xiamen, China

“Critical Characteristics of Tumor Biopsy for Biomarker Evaluation”

Organizer, moderator

Early Drug Development Meeting

September 27, 2016

Bethesda, MD

Chen, Alice P.

34

“CTCAE v5”

Presenter, CRP Education Breakout: Nursing/CRP

Alliance Fall Annual Meeting

November 4, 2016

Chicago

“NCI-Molecular Analysis for Therapy Choice (NCI-MATCH / EAY131): Trial Status Overview”

Presenter, Community Oncology Committee

Alliance Fall Annual Meeting

November 5, 2016

Chicago

“Drug Development through the Division of Cancer Treatment and Diagnosis”

National Taiwan University

Taipei, Taiwan

November 22, 2016

“Drug Development through the National Cancer Institute”

Keynote Speaker

The 5th International Symposium on Bioactivities and Diseases Prevention of Phytochemicals and Natural Products for Health

NCYU, Chiayi, Taiwan

November 25, 2016.

“CTCAE, PROCTCAE and Attributions”

Toxicity Attribution PreWorkshop Conference

Houston, MD

February 10, 2017

“Developmental Therapeutics Clinic”

Translational Cancer Biology Workshop

Panelist

Bethesda, MD

April 4, 2017

NCI Medical Oncology Fellowship Journal Club

Presenter

Bethesda, MD

April 21, 2017

“NCI MATCH Update”

COG Meeting

ASCO

Bethesda, MD

June 3, 2017

Chen, Alice P.

35

“NCI MATCH”

Meet the Expert

NCI Booth, ASCO

June 3, 2017

“CTCAE V5”

Meet the Expert

NCI Booth, ASCO

June 3, 2017

“NCI MATCH”

NCI Pharm meeting

ASCO

June 3, 2017

TRC 102

Poster discussion

ASCO

June 5, 2017

“CTCAE v5”

presenter

FDA-NCI Meeting

Rockville

June 15, 2017

Clinical Trial Advances

Panelist

Cancer Moonshot: One Year Later

Washington DC

June 27, 2017

“Trial Status Overview”

Presenter

MATCH ERKi Arm PI Orientation

July 12, 2017

Panelist

ICLIO 2nd Policy Summit

Washington, DC

August 18, 2017

“NCI Perspective: Attribution of Adverse Event in Early Phase Clinical Trials”

Attribution Workshop

Silver Spring, MD

September 15, 2017

Chen, Alice P.

36

“Building the Diagnostic Cockpit for the Future: Oncology”

Academy for Radiology and Biomedical Imaging Research

Rockville, MD

September 18, 2017

“Translational Science-From Assay Development to Clinical Implementation”

Moderator

“Improving Biopsies for Research Purposes at the DTC”

Presenter

2017 CTEP Early Drug Development Meeting

Rockville, MD

September 25, 2017

WICR Career Mentoring Session

Mentor

Philadelphia, PA

October 27, 2017

AACR Press Conference

Presenter

Philadelphia, PA

October 27, 2017

“NCI-MATCH (EAY131): A New Paradigm in the Era of Genomic Oncology”

Plenary Session

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Philadelphia, PA

October 28, 2017

“A Phase II Trial of cabozantinib (XL-184) in metastatic refractory soft tissue sarcoma”

CTOS

Maui, Hawaii

November 9, 2017

“TRC 102 Clinical Development”

Tracon Investigator Meeting

San Diego, CA

December 7, 2017

“Early Drug Development”

NCI Fellowship Core Lecture

Bethesda MD

March 9, 2018

Chen, Alice P.

37

“Taking Genomic Testing into Cancer Treatment Trials”

Forum Onkologie

Salzburg, Austria

March 16, 2018

“Clinical and Translational Impact of MATCH”

FTF NCI MATCH Meeting

Bethesda, MD

April 3, 2018

“CTCAE: Common Terminology Criteria for Adverse Events”

Presenter and participant

2018 Annual INC Neonatal Scientific Workshop

Bethesda, MD

April 12, 2018

Panel Discussion and Public Comments on Other Targets and Non-Relevant Targets

Panelist

FDA/OCE Public Meeting on Relevant Molecular Targets in Pediatric Cancers: Applicability to

Therapeutic Investigation FDARA 2017

Silver Spring, MD

April 20, 2018

CTEP SOLICITATION LEADERSHIP

Ziv-Aflibercept 2005

Aminoflavone 2010

MK 1775 July 2012

TRC 102 2014

BMN 673 2014

GRANT REVIEW

Breast Cancer Now 2017

Cancer Research UK 2017, 2018

Gateway for Cancer Research

Lustgarten Review

Wellbeing of Women Research Grant

REVIEWER

BMC Research Notes

Breast Cancer: Basic and Clinical Research

Cancer

Clinical Investigations

Clinical Cancer Research

Chen, Alice P.

38

Cancer Research

Future in Oncology

International Journal of Molecular Sciences

Molecular Pharmacology

New England Journal of Medicine

Pharmaceutical Patent Analyst

PLOS

Recent Patents on Anti-Cancer Drug Discovery 2017

Science in Translation

Seminars in Cell and Developmental Biology

Tumor Biology